Glaukos Corporation (GKOS)
NYSE: GKOS · IEX Real-Time Price · USD
120.73
+2.02 (1.70%)
At close: Jul 19, 2024, 4:00 PM
120.84
+0.11 (0.09%)
After-hours: Jul 20, 2024, 12:58 PM EDT
Glaukos Revenue
Glaukos had revenue of $326.43M in the twelve months ending March 31, 2024, with 12.92% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $85.62M with 15.86% year-over-year growth. In the year 2023, Glaukos had annual revenue of $314.71M with 11.26% growth.
Revenue (ttm)
$326.43M
Revenue Growth
+12.92%
P/S Ratio
18.63
Revenue / Employee
$359,905
Employees
907
Market Cap
6.08B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
Dec 31, 2018 | 181.28M | 22.02M | 13.83% |
Dec 31, 2017 | 159.25M | 44.86M | 39.21% |
Dec 31, 2016 | 114.40M | 42.70M | 59.55% |
Dec 31, 2015 | 71.70M | 26.11M | 57.28% |
Dec 31, 2014 | 45.59M | 24.64M | 117.64% |
Dec 31, 2013 | 20.95M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.32B |
Elanco Animal Health | 4.37B |
Bausch + Lomb | 4.31B |
Acadia Healthcare Company | 2.99B |
Masimo | 1.98B |
Stevanato Group | 1.18B |
HealthEquity | 1.04B |
Krystal Biotech | 95.95M |
GKOS News
- 11 days ago - This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
- 12 days ago - Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31 - Business Wire
- 5 weeks ago - Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock - Business Wire
- 7 weeks ago - Glaukos Announces Participation in Upcoming Investor Conferences - Business Wire
- 2 months ago - Glaukos Announces First Quarter 2024 Financial Results - Business Wire
- 3 months ago - Glaukos Announces the Release of its 2023 Sustainability Report - Business Wire
- 3 months ago - Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1 - Business Wire
- 3 months ago - Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant) - Business Wire